Caitlin Delaney about the power of genomics to transform outcomes
Caitlin Delaney, Chair of the National Patient Advisory Committee and Patient-Partnered Research at VCCC Alliance, shared on LinkedIn:
“Today I found out that my disease is progressing and I was kicked off the clinical trial. I am actually delighted to be off this particular trial as the toxic side effects have significantly impacted my quality of life.
Just 1 week ago I was talking of the power of genomics to transform outcomes at the final Genomics Policy Rountable held by Rare Cancers Australia.
Today I am turning to genomics yet again to help change the trajectory of my stage 4 disease. I will hopefully have a new biopsy of tumour tissue for genetic testing to help identify markers that will guide the next best course of treatment.
This treatment will most likely be TDXD – which I will have to self fund at up to $13,000 every 3 weeks. There are no options for co-pay or compassionate access with this drug for ovarian (and many other) cancers here in Australia.
I know what I want for Christmas (I have always had expensive taste)! Watch this space as I will be launching a fundraising campaign soon…”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023